BioTissue Technologies AG
BioTissue AG english
Corporate-News announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
New clinical data confirm the success of treatment with “skin from the tube”
– Superlative clinical results
– Significant cost advantages
– Appreciable improvement in quality of life
Freiburg, May 21, 2001 -BioTissue Technologies AG, listed on the Neuer Markt
segment of the Frankfurt Stock Exchange under SIN 618061 has published new
clinical data on its BioSeed-S skin substitute cultured from the patients’ own
cells. The data attests the superlative clinical results and pharmaceutical-
economic investigations document the potential savings to be made when treating
chronic wounds with BioSeed-S as compared with other methods.
In the course of open multi-center monitoring of the application, 79 patients
were treated for 95 chronic open wounds – some of them had been treated with
conservative methods for years without any successes being achieved. For the
treatment with BioSeed-S a small piece of skin is removed from each patient and
the cells are isolated in the BioTissue labs and then cultured; thereafter the
new cells are transplanted back onto the respective patient’s wound by means of
a gel-like bio-adhesive. In the process, 44.2 percent of this wounds, which had
hitherto resisted therapy, were completed healed within an average 80.5 days. In
total, 87 percent of all wounds treated improved significantly or had healed
within the first 42 days of having been treated by means of a BioSeed-S
transplantation. “Given the severity of the wounds in these problematic cases,
the percentage achieved are truly remarkable,” declared Dr. Matthias Augustin,
who headed monitoring of the program.
In a validated study, treatment with BioSeed-S showed a significant improvement
in the patients’ quality of life.
During the treatment, by means of a questionnaire we likewise compared the
direct costs incurred by the health insurance companies with those of customary
forms of treatment. The average costs incl. the physicians’ inputs came to DM
8765 in the case of treatment with BioSeed-S and were thus considerably lower
than the costs of other, conservative forms of treatment, which entail annual
outlays of up to DM 30,000. Chronic wounds, which often persist for years,
create costs of several billion deutschmarks in Germany – where there are about
three million patients.
“We are consistently working to improve the database on our products, proving
their effectiveness and cost-savings potential. Increasingly, we tend to present
the results in discussions with health insurance companies, users and in sales
activities,” states Dr. Wilhelm Brandner, CEO of BioTissue.
Since mid-April, BioSeed-S has been marketed by Baxter International Inc. under
the terms of an exclusive and worldwide cooperation agreement. In coming months,
the product will be launched on the first markets outside Germany.
The new clinical data is soon to be released in various scientific publications.
Any more questions?
Simply contact:
Mr. Martin Braendle
Investor- and
Public Relations Manager
BioTissue Technologies AG
Bismarckallee 9
D-79098 Freiburg
Tel 49 761 7675110
Fax 49 761 7675155
martin.braendle@biotissue-tec.com
end of message, (c) DGAP 21.05.2001
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden